Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
4.35% $1.440
America/New_York / 23 apr 2024 @ 10:17
FUNDAMENTALS | |
---|---|
MarketCap: | 358.44 mill |
EPS: | -0.390 |
P/E: | -3.69 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 248.92 mill |
Avg Daily Volume: | 1.014 mill |
RATING 2024-04-22 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.69 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.63x |
Company: PE -3.69 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0502 (-103.48%) $-1.490 |
Date: 2024-04-23 |
Expected Trading Range (DAY) |
---|
$ 1.339 - 1.523 ( +/- 6.43%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-05 | Thomasian Harry Jr. | Buy | 135 714 | Common Stock |
2024-04-05 | Thomasian Harry Jr. | Sell | 67 389 | Common Stock |
2024-04-05 | Thomasian Harry Jr. | Buy | 135 714 | Restricted Stock Units |
2024-04-05 | Thomasian Harry Jr. | Sell | 135 714 | Restricted Stock Units |
2024-04-05 | Perez Jeffrey Thomas | Buy | 142 857 | Common Stock |
INSIDER POWER |
---|
34.55 |
Last 99 transactions |
Buy: 8 317 118 | Sell: 3 939 504 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.440 (4.35% ) |
Volume | 0.0916 mill |
Avg. Vol. | 1.014 mill |
% of Avg. Vol | 9.03 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.380 | N/A | Active |
---|
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.